147 results about "Drug regimen" patented technology

An automated small items dispensing apparatus is disclosed. In a preferred embodiment, the invention includes a networked, programmable, automatic medication items dispensing apparatus for use by individual patients who are enrolled in a medication protocol or medication therapy regimen. The device is located separate from the patient's health care provider's facility, such as in the patient's home.

A method is provided for encouraging patient compliance with a medicine regimen that includes interaction with the patient. The method includes the steps of providing a database which includes information regarding each patient. Information is supplied to the database by smart packages and other stakeholders. The information in the database is used to construct a patient report that may be viewed by the patient and others. Information in the patient report includes data on the patient's compliance, side effects of the medicine, expected results, interactions with other medicines, statements complimenting compliance, and warnings discouraging non-compliance. The patient report may be accessed by a common communication means such as the Internet.

A medication dispenser is provided which includes compartments uniquely arranged with respect to time, for example, by time of day and/or day of week. Each compartment may contain pills in accordance with a pharmaceutical regimen such that consuming the pills within the compartments at the appropriate time as arranged with respect to time may maintain a patient's compliance with the pharmaceutical regimen. Additionally, a medication compliance and management method is provided which includes the steps of a) reviewing a pharmaceutical regimen of a patient to reduce a complexity of the pharmaceutical regimen, b) providing a quantity of medication dispensers in accordance with the reviewed pharmaceutical regimen with pills of the pharmaceutical regimen organized within the medication dispensers to further reduce the complexity of the pharmaceutical regimen, c) tracking the quantity of provided medication dispensers to determine when the quantity of medication dispensers will be depleted, d) contacting a prescribing doctor to obtain authorization to refill additional medication dispensers, and e) delivering refilled medication dispensers to the patient.

Without timely reminders, certain individuals may be highly unlikely to complete various tasks scheduled for completion. For example, medicinal therapy regimen patients often have difficulty in remembering to take their prescribed medications in accordance with care provider specified instructions. By providing a reminder prompt generation system that utilizes machine-learning and/or artificial intelligence to determine appropriate reminder times and modalities for providing automated-prompting notifications to users, the users' adherence to scheduled task completions can be significantly increased.

Described herein is a system for monitoring gene expression for diagnosing and monitoring inflammation disorders, and for monitoring gene expression in inflammation disorders in response to a particular drug treatment reginmen. This system for detecting nucleic acid expression in a body fluid uses an isolated polynucleotide to detect expression of a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 5; SEQ ID NO:11; SEQ ID NO:17; and SEQ ID NO: 23. These nucleic acids are differentially expressed in body fluid in an individual with a disease criterion for a disease as listed in Table 1 as compared to an individual without the disease criterion.

A system and method of identifying patients with an increased risk for medication misuse as a result of their physical condition or inability to follow a prescription drug regimen. This is accomplished by an onsite evaluation of the patient, their physical condition and medication usage, including prescriptions, over the counter medications, herbals and food interactions, by a qualified individual. The results of this evaluation are provided to a database that generates a report comprising a patient's vital signs, medication interactions, prescription changes, prescription renewals, discontinued medications, evaluation of a patient's compliance with their medication regimen and education approved for to assist the patient with their compliance for review by the patient's primary care physician, additional physicians treating the patient, authorized organizations, such as HMOs, gardians or other authorized individual. With this knowledge the physician can identify a current or potential problem and can recommend changes to a patient's prescription drug regimen or education regarding drug regimens to correct the problem.

Cardiac treatment methods and devices providing templates representative of past tachyarrythmia events, each template associated with a therapy. A cardiac waveform is detected, and if it corresponds to a particular template associated with a previous therapy that was satisfactory in terminating a past event, the previous therapy is delivered again. If unsatisfactory, the previous therapy is eliminated as an option. If, for example, the previous therapy was an antitachycardia pacing therapy unsatisfactory in terminating the past tachyarrythmia event, delivery of the antitachycardia pacing therapy is eliminated as an option. Instead of ATP therapy, one or more of a cardioversion, defibrillation, or alternate anti-tachycardia pacing therapy may be associated with the particular template. Cardiac waveforms and templates may correspond in terms of one or more of morphology, timing, drug regimen, medication, neural activity, patient activity, hemodynamic status, cardiac tissue impedance, transthoracic impedance, or other information corresponding to the episode.

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

A method of providing items required for a complex drug regimen. In a preferred embodiment the method includes the steps of disposing a plurality of different drugs in corresponding drug compartments within a container; and providing drug identification information visually associated with each drug compartment containing a drug. The invention also includes a kit for a complex drug regimen. In a preferred embodiment the kit includes a kit container including a plurality of drug compartments, each drug compartment adapted to contain a drug; a plurality of different drugs disposed in the drug compartments; and drug identification information visually associated with each drug compartment containing a drug.

The invention provides antineoplastic composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase type I enzyme activity.